NTV Asset Management 13F: New $884K Stake in EW

NTV Asset Management disclosed a new stake in Edwards Lifesciences Corporation EW, acquiring 10,240 shares valued at about $883,917. The firm revealed the investment in a Form 13F filing submitted to the Securities and Exchange Commission on October 23, 2026.

EW Edwards Lifesciences Corporation

$89.62 ▲ +5.03% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in NTV Asset Management's Edwards Lifesciences Corporation Position

The fund opened a brand-new position in the medical device maker during the period, bringing onto its books a total of 10,240 shares. Based on the market close around the filing date, the reported value of the stake reached approximately $883,917. Because this was a newly initiated holding, there was no prior share count or percentage comparison to report.

Other Institutional Activity in Edwards Lifesciences Corporation

Other large investors adjusted their positions in Edwards Lifesciences Corporation around the same time. Mutual of America Capital Management grew its holdings by 19,631 shares, ending with 79,114 shares worth about $6.83 million. Investment House reduced its stake by 62,285 shares to finish with 56,715 shares valued at approximately $4.90 million. Bank Of New York Mellon Corporation cut its holdings by 2,652,871 shares, leaving it with 14,084,483 shares worth about $1.25 billion. Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main raised its position by 190,900 shares to hold 13,002,965 shares valued at roughly $1.16 billion. Ninety One UK Ltd trimmed its stake by 393,558 shares, ending with 11,943,675 shares worth about $1.06 billion.

Edwards Lifesciences Corporation Stock Up 0.8%

The shares recently traded around $89.07, sitting close to the level where the stock closed on the filing date. That puts the equity up about 1.1% above its 50-day moving average and roughly 4.5% higher than its 200-day moving average.

Recent Earnings

Edwards Lifesciences Corporation reported trailing twelve month revenue of $6.51 billion and earnings of $1.71 per share. The company posted a net profit margin of 15.4% and a return on equity of 9.2%, with its next quarterly financial update scheduled for November 4, 2026.

Dividend

The company does not pay a dividend to shareholders, keeping its dividend payout ratio at 0.0%.

Insider Buying and Selling at Edwards Lifesciences Corporation

Company insiders completed several transactions in late summer and early autumn. Officer Annette Bruls sold 2,644 shares on August 28, 2026, at an average price of $89.98 for a total value of $237,907. Officer Andrew M Dahl disposed of 544 shares on August 31, 2026, at $91.06 per share totaling $49,534. Officer Daniel J Lippis sold 619 shares on September 11, 2026, at $87.51 for $54,169, and later sold another 619 shares on October 8, 2026, at $85.65 for $53,017.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. JP Morgan maintained an Overweight rating while lifting its target to $105.00 on July 24, 2026. Piper Sandler reiterated an Overweight rating with a $101.00 price target on the same day. Leerink Partners upgraded the stock to Outperform on July 25, 2026, raising its target to $101.00. BTIG reiterated a Buy rating with a $110.00 target on September 11, 2026. Barclays initiated coverage with an Overweight rating and a $110.00 price target on October 7, 2026. Overall, the stock carries a consensus buy rating and a mean price target of $101.39 across 27 analyst opinions.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation focuses on specialized medical technologies designed to treat advanced cardiovascular diseases. The Irvine, California-based company produces transcatheter heart valve replacement systems, including the SAPIEN valve family, alongside repair solutions for mitral and tricuspid heart valves under the PASCAL and EVOQUE brands. Institutional interest remains active as the healthcare firm develops minimally invasive options for heart patients.

Bottom Line

Investors will look toward the upcoming earnings release on November 4, 2026, for further insight into revenue growth and margin trends. Future SEC filings will show whether institutional funds continue adjusting their positions in the medical device sector.